@article{e9e59764661f440388b41537ab5205d9,
title = "The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells",
abstract = "The tissue-specific drivers of neurosarcoidosis remain poorly defined. To identify cerebrospinal fluid (CSF) specific, antigen-driven T and B cell responses, we performed single-cell RNA sequencing of CSF and blood cells from neurosarcoid participants coupled to T and B cell receptor sequencing. In contrast to pulmonary sarcoidosis, which is driven by CD4 T cells, we found CD8 T cell clonal expansion enriched in the neurosarcoid CSF. These CSF-enriched CD8 T cells were composed of two subsets with differential expression of EBI2, CXCR3, and CXCR4. Lastly, our data suggest that IFNγ signaling may distinguish neurosarcoidosis from other neurological disorders.",
keywords = "Interferon, Neurosarcoidosis, Sarcoidosis, Single-cell RNA sequencing, T cells, TCR sequencing",
author = "Paley, {Michael A.} and Baker, {Brandi J.} and Dunham, {S. Richard} and Nicole Linskey and Claudia Cantoni and Kenneth Lee and Hassman, {Lynn M.} and Jennifer Laurent and Roberson, {Elisha D.O.} and Clifford, {David B.} and Yokoyama, {Wayne M.}",
note = "Funding Information: MAP receives research support from Lilly paid to the institution and received consultant fees from AbbVie, JK Market Research, and Priovant Therapeutics. The authors have no other declarations of interest.The authors thank the study participants for their generous and enthusiastic participation. We thank Gregory F. Wu, Anne H. Cross, Laura Piccio, and Dana C. Perantie for support with sample collection and constructive comments. We thank Naresha Saligrama and Tarin Bigley for manuscript review and critical feedback. MAP was supported by the Rheumatology Research Foundation and the Arthritis National Research Foundation. SRD was supported by the NeuroNEXT Network. CC was supported by the National Multiple Sclerosis Foundation. LMH was supported by an unrestricted grant from Research to Prevent Blindness. Funding for this project was provided by the Barnes-Jewish Hospital Foundation (WMY), a grant from the McDonnell Center for Cellular and Molecular Neurobiology (WMY), the Arthritis National Research Foundation (MAP), and the Washington University Rheumatic Diseases Research Resource-based Center (EDOR; P30-AR073752). The funding organizations had no role in the design or conduct of this research. Funding Information: MAP receives research support from Lilly paid to the institution and received consultant fees from AbbVie, JK Market Research, and Priovant Therapeutics. The authors have no other declarations of interest. Publisher Copyright: {\textcopyright} 2022",
year = "2022",
month = jun,
day = "15",
doi = "10.1016/j.jneuroim.2022.577860",
language = "English",
volume = "367",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
}